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410The Effect of Renal Function and
Hemodialysis Treatment on Plasma
Vasopressin and Copeptin Levels
Esmée M. Ettema1, Judith Heida1, Niek F. Casteleijn1, Lianne Boesten2, Ralf Westerhuis3,
Carlo A.J.M. Gaillard1, Ron T. Gansevoort1, Casper F.M. Franssen1 and Debbie Zittema1
1Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen,
Groningen, the Netherlands; 2Department of Laboratory Medicine, IJsselland Hospital, Capelle aan den IJssel, the Netherlands;
and 3Dialysis Center Groningen, Groningen, the NetherlandsIntroduction: Copeptin is increasingly used in epidemiological studies as a substitute for vasopressin. The
effect of renal function per se on copeptin and vasopressin concentrations as well as their ratio have,
however, not been well described.
Methods: Copeptin and vasopressin levels were measured in 127 patients with various stages of chronic
kidney disease, including 42 hemodialysis patients and 16 healthy participants in this observational study.
Linear (segmental) regression analyses were performed to assess the association between renal function
and copeptin, vasopressin and the C/V ratio. In addition, clearance of copeptin and vasopressin by
hemodialysis was calculated.
Results: Both copeptin and vasopressin levels were higher when renal function was lower, and both
showed associations with plasma osmolality. The C/V ratio was stable across renal function in subjects
with an eGFR >28 ml/min per 1.73 m2. In contrast, the C/V ratio increased with worsening renal function in
patients with eGFR#28 ml/min per 1.73 m2. During hemodialysis, the initial decrease in vasopressin levels
was greater compared with copeptin and, consequently, the C/V ratio increased. This was, at least in part,
explained by a greater dialytic clearance of vasopressin compared with copeptin.
Discussion: Our data indicate that copeptin is a reliable substitute for vasopressin in subjects with an eGFR
>28 ml/min per 1.73 m2, whereas at an eGFR #28 ml/min per 1.73 m2, that is, CKD stages 4 and 5, a
correction for renal function is required in epidemiological studies that use copeptin as a marker for
vasopressin. Intradialytic copeptin levels do not adequately reﬂect vasopressin levels because vasopressin
clearance by hemodialysis is higher than that of copeptin.
Kidney Int Rep (2017) 2, 410–419; http://dx.doi.org/10.1016/j.ekir.2017.01.006
KEYWORDS: chronic kidney disease; copeptin; hemodialysis; kidney function; vasopressin
ª 2017 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).A rginine vasopressin is essential for maintainingﬂuid homeostasis in the human body. Vasopressin
is released from the posterior pituitary gland in
response to hyperosmolality, hypotension, and hypo-
volemia.1 This hormone regulates water balance via V2
receptor–mediated renal water reabsorption and in-
creases blood pressure via V1 receptor–mediated
vasoconstriction. In addition to these important phys-
iological effects, evidence is emerging that vasopressin
also has deleterious effects and may play a role in thespondence: Esmée M. Ettema, University of Groningen,
rsity Medical Center Groningen, Department of Internal
ine, Division of Nephrology, Hanzeplein 1, 9713 GZ
ngen, the Netherlands. E-mail: e.m.ettema@umcg.nl
ved 24 August 2016; revised 21 December 2016; accepted 13
ry 2017; published online 23 January 2017progression of renal disease.2 Experimental data
showed that desmopressin, a selective V2 receptor
agonist, induced transient proteinuria3,4 and worsened
progression of CKD.3
Copeptin, a fragment of the vasopressin precursor
preprovasopressin, is used as a substitute for esti-
mating vasopressin levels because it is easier to measure
and allegedly more stable ex vivo.5–8 When pre-
provasopressin is split in the pituitary gland, copeptin
and vasopressin are secreted in equimolar amounts into
the circulation.5,8,9 Several studies have investigated
the reliability of copeptin as a marker for vasopressin
and have demonstrated a strong correlation between
plasma vasopressin and copeptin levels in healthy in-
dividuals5,7,10,11 as well as in critically ill patients.5,12,13
In addition, it has been shown that the plasma con-
centration of both peptides responds similarly toKidney International Reports (2017) 2, 410–419
EM Ettema et al.: Effect of Clearance on Copeptin-Vasopressin Ratio CLINICAL RESEARCHchanges in ﬂuid status and plasma osmolality.6,14,15
Given the recent interest in the effects of vasopressin
on kidney health, measurement of copeptin in epide-
miological studies gains popularity.16,17
Vasopressin as well as copeptin are small-sized
molecules (1 and 5 kDa, respectively),5,18 and both
are therefore theoretically subjected to renal clearance.
As yet, it is not clear whether renal function affects
both analytes to the same extent and therefore whether
copeptin can be used as marker for vasopressin in pa-
tients with impaired renal function. Several studies
found an inverse association between copeptin and
renal function.10,19–23 However, concurrent measure-
ment of vasopressin is pivotal to understand whether
increased copeptin levels accurately reﬂect vasopressin
levels in patients with chronic kidney disease (CKD).24
In case copeptin and vasopressin are cleared similarly,
the copeptin-to-vasopressin ratio (C/V ratio) is expected
to be stable across the full range of kidney function.
In hemodialysis patients, differential extracorporal
clearance could also result in divergent plasma copep-
tin and vasopressin levels, because copeptin is larger
than vasopressin and may therefore be cleared less by
the artiﬁcial kidney. However, copeptin removal by
hemodialysis has not yet been studied.
Because copeptin is used as a surrogate for vaso-
pressin in patients with decreased renal function while
it is unknown whether renal function affects copeptin
and vasopressin concentrations in a similar fashion, we
investigated in the present study the association of
copeptin and vasopressin in subjects over a broad
range of renal function as well as the kinetics of these
analytes during hemodialysis.
METHODS
Participants and Study Protocol
For this study, samples were used of subjects that
participated in 4 studies performed at the Nephrology
Department of the University Medical Center Gronin-
gen between March 1, 2010 and March 1, 2016.24 The
cohort was established from patients with either auto-
somal dominant polycystic kidney disease or IgA ne-
phropathy with normal and impaired renal function
from whom plasma vasopressin and copeptin levels
were available and in hemodialysis patients partici-
pating in a study on vasopressin. In these studies,
blood samples were drawn according to a strict pro-
tocol to allow reliable measurement of plasma copeptin
and vasopressin levels after completion. Blood was
collected in chilled ethylenediamine tetraacetic acid
tubes, immediately centrifuged in a cooled centrifuge
at 4 C, and the plasma supernatant was stored frozen
at 80 C in plastic 2 ml aliquots until measurementKidney International Reports (2017) 2, 410–419that took place within 1 year of storage. Samples were
available of healthy subjects (n ¼ 15), CKD patients
with either autosomal dominant polycystic kidney
disease (n ¼ 54) or IgA nephropathy (n ¼ 16), and
hemodialysis patients (n ¼ 42). All participants gave
written informed consent. The studies were performed
in accordance with the principles of the Declaration of
Helsinki and approved by the Medical Ethical Com-
mittee of the University Medical Center Groningen.
Outcome and Measurements
Theprimary outcome in the present study is the C/V ratio
across different stages of renal function and its associa-
tion with estimated glomerular ﬁltration rate (eGFR).
Vasopressin was measured by radioimmunoassay (DRG
International Inc., Springﬁeld, NJ) with a lower limit of
detection of 0.25 pmol/l and a functional assay sensi-
tivity of 0.5 pmol/l with 2.0 ml of plasma. The interassay
and intraassay coefﬁcients of variation were both <7%
in the low and high concentration range (i.e., around 4
and 20 pmol/l, respectively). Copeptin was measured by
an automated sandwich immunoﬂuorescent assay (CT-
proAVP; Thermo Fisher Scientiﬁc, B.R.A.H.M.S GmbH,
Hennigsdorf, Germany)with a lower limit of detection of
0.9 pmol/l and a functional assay sensitivity of 2 pmol/l.
The interassay and intraassay coefﬁcients of variation for
copeptin concentrations>15 pmol/l were<5% and 4%
respectively.
In healthy subjects and in patients with CKD, GFR
was estimated from plasma creatinine concentration,
age, and sex with the Chronic Kidney Disease Epide-
miology Collaboration equation that expresses GFR
indexed for 1.73 m2 body surface area.25 In hemodial-
ysis patients, residual renal function was assumed to be
present when diuresis was $200 ml/day and GFR was
estimated as 0.5  (24-hour urea clearance þ 24-hour
creatinine clearance) and similarly expressed per
1.73 m2 body surface area.26 A 24-hour urine sample
was used to estimate residual renal function, this urine
sample is collected every 4 months after the longest
interdialytic interval preceding the ﬁrst dialysis session
of the week (i.e., Monday or Tuesday).
Plasma and urine creatinine was measured with the
Roche enzymatic creatinine assay. Plasma and urine
urea were measured with the colorimetric method on a
Roche Modular analyzer. Plasma sodium was measured
with the indirect method of ion-selective electrode
(Roche Modular, Mannheim, Germany) and plasma
osmolality was measured by freezing-point depression
(Osmo Station Osmometer, Kyoto, Japan).
In hemodialysis patients, blood samples for mea-
surement of plasma copeptin and vasopressin were
collected from the arterial line at the initiation of411
CLINICAL RESEARCH EM Ettema et al.: Effect of Clearance on Copeptin-Vasopressin Ratiohemodialysis and at 30 minutes on dialysis. Clearance
of copeptin and vasopressin by hemodialysis was
calculated as described previously27 using simulta-
neously collected efferent dialysate and predialyzer
blood. A detailed description is provided as
Supplementary Item S1. At the same time, copeptin and
vasopressin were also measured in postdialyzer blood
samples to evaluate the possible change in plasma
concentration over the dialyzer.
Hemodialysis was conducted in a 3-times weekly
4-hour schedule with a low-ﬂux polysulphone dialyzer
(F8 or F10, Fresenius Medical Care, Bad Hamburg,
Germany). The ultraﬁltration volume was set to achieve
dry weight at the completion of the hemodialysis
session. Speciﬁcations of the dialysis treatment are
provided as Supplementary Item S2. In a subgroup of
27 hemodialysis patients, blood samples were
also collected during dialysis at 60, 120, 180, and
240 minutes (just before the end of the treatment)
intradialysis. Intradialytic copeptin and vasopressin
concentrations were corrected for hemoconcentra-
tion,28 as described in Supplementary Item S3.
Statistical Analysis
Normally distributed variables are presented as
means  SDs, and variables with a skewed distribution
as medians and interquartile ranges (IQRs). Categorical
data are given as numbers and percentages. For com-
parison of baseline characteristics, the participants
were subdivided into 4 subgroups according to kidney
function: group 1: eGFR $90 ml/min per 1.73 m2
(n ¼ 16); group 2: eGFR between 45 and 89 ml/min per
1.73 m2 (n ¼ 33); group 3: eGFR <45 ml/min per
1.73 m2 not on hemodialysis (n ¼ 36); group 4:
eGFR <15 ml/min per 1.73 m2 on hemodialysis
(n ¼ 42). Differences among the 4 study groups were
tested for statistical signiﬁcance with a chi-square test,
or 1-way analysis of variance or Kruskal-Wallis test
with post hoc testing for multiple comparisons. Uni-
variate and multivariate regression analyses were used
to assess associations. Nonnormally distributed vari-
ables (i.e., copeptin, vasopressin, and osmolality) were
log transformed to fulﬁll the requirements of normal
distribution of the residuals for regression analysis. In
the regression analyses, eGFR is used as a continuous
variable to be able to perform break-point analyses.
Segmented linear regression analysis was used to
determine possible breakpoints in the association of
renal function with the C/V ratio. Differences in
copeptin, vasopressin, and the C/V ratio between he-
modialysis patients with and without residual renal
function were analyzed using the Wilcoxon signed
rank test. This same test was used to analyze copeptin
and vasopressin during hemodialysis, with Bonferroni412correction for multiple testing, and to study differences
in hemodialysis clearance characteristics of copeptin
and vasopressin. Spearman correlation was used to
assess correlations between copeptin, vasopressin, the
C/V ratio, and dialysis vintage. Analyses were per-
formed with SPSS version 22.0 and GraphPad Prism
version 5.0 (GraphPad Software, San Diego, CA).




Table 1 shows the characteristics of the entire study
group and the subgroups stratiﬁed according to renal
function. Age, plasma osmolality, blood pressure, use
of antihypertensive medication, and plasma vaso-
pressin and copeptin levels were progressively higher
in subgroups with lower renal function (Table 1).
Copeptin and Vasopressin
Average plasma copeptin and vasopressin concentra-
tion in the overall group of participants was
25.9 pmol/l and 2.2 pmol/l, respectively. As shown in
Table 1, plasma copeptin and vasopressin levels
were signiﬁcantly higher in subjects with an eGFR
<45 compared with subjects with eGFR $90 ml/min
per 1.73 m2 (P < 0.05) and in patients on dialysis
compared with participants not on dialysis (P < 0.001).
The C/V ratio in patients on dialysis was signiﬁcantly
higher than for the other 3 groups (P < 0.001), whereas
no signiﬁcant differences were observed among the
3 nondialysis subgroups.
Overall, a strong association was found between
copeptin and vasopressin (b ¼ 0.77; P < 0.001). The
association between copeptin and vasopressin differed
between nondialysis and dialysis patients. “Dialysis
treatment” was, therefore, added to the linear regres-
sion model, which had indeed a signiﬁcant effect
(b ¼ 0.58; P < 0.001). Therefore, the hemodialysis
patient group was analyzed separately. Copeptin and
vasopressin remained strongly associated in the non-
dialysis subjects, including healthy individuals and
CKD patients (n ¼ 85, b ¼ 0.75; P< 0.001), as well as in
the hemodialysis patients (n ¼ 42, b ¼ 0.84; P < 0.001)
(Figure 1).
Effect of Renal Function on Copeptin and
Vasopressin and Their Ratio in Nondialysis
Subjects
In nondialysis subjects, a signiﬁcant inverse association
between renal function and copeptin was found
(Table 2 and Figure 2a). Associations were also
observed between renal function and plasma osmolality
(b ¼ 0.78; P < 0.001), and between plasma osmolalityKidney International Reports (2017) 2, 410–419
Table 1. Characteristics of the overall group of participants and for participants stratiﬁed according to renal function








(n [ 42) P value
Age (yr) 28  10 47  10 51  8 63  18 <0.001a
Males 8 (50) 17 (52) 19 (53) 30 (71) 0.21
eGFR (ml/min per 1.73 m2) 103  9 64  15 25  9 NA
RRF (ml/min per 1.73 m2) — — — 0.4 (0.0–2.2) NA
Plasma vasopressin (pmol/l) 0.7 (0.3–1.5) 1.2 (0.8–2.6) 2.0 (1.2–3.2) 5.0 (3.3–6.8) <0.001b
Plasma copeptin (pmol/l) 6.1 (2.7–8.3) 9.0 (6.6–18.2) 25.8 (9.4–36.7) 170.0 (102.6–280.5) <0.001b
Copeptin-vasopressin ratio 5.3 (3.5–8.2) 7.1 (5.1–10.2) 11.4 (6.7–17.5) 42.6 (31.3–57.4) <0.001b
Plasma osmolality (mOsm/kg) 282 (279–284) 287 (284–290) 300 (294–303) 305 (295–310) <0.001b
Volume 24-hour urine (ml) 2195  936 2166  705 2489  942 336  423 <0.001a
SBP (mm Hg) 128  10 130 14 132  12 143  25 <0.01a
DBP (mm Hg) 78  9 84  19 82  9 72  13 <0.01a
Medication
ACEI or ARB 4 (25) 19 (58) 33 (92) 8 (19) <0.001
Beta-blocker 0 (0) 3 (9) 11 (31) 29 (69) <0.001
CBB 0 (0) 1 (3) 12 (33) 13 (31) <0.01
Diuretic 0 (0) 2 (6) 12 (33) 10 (24) <0.01
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; DBP, diastolic blood pressure; eGFR, estimated glomerular ﬁltration
rate; HD, hemodialysis; NA, not applicable; RRF, residual renal function; SBP, systolic blood pressure.
Variables are presented as mean  SD, n (%), or median and (interquartile range).
aAnalysis of variance with post hoc test Bonferroni: age differed among all 4 groups (P < 0.01) except between patients with an eGFR <45 and 45 to 89 ml/min per 1.73 m2. Volume of
24-hour urine was lower in HD patients compared with the other 3 groups (P < 0.001). SBP was higher in HD patients compared with the 3 other groups (P < 0.05). DBP was lower in HD
patients compared with patients with an eGFR between <45 and 45 to 89 (P < 0.05).
bKruskal-Wallis with post hoc test for multiple comparisons: osmolality differed among all 4 groups (P < 0.001), except for participants with an eGFR between 45 to 89 and $90 and
between patients with an eGFR <45 and on HD. Vasopressin and copeptin levels were higher in HD patients compared with the 3 other groups (P < 0.01) and in the group with an
eGFR <45 compared with $90 (P < 0.05). The copeptin-vasopressin ratio was higher in HD patients compared with the 3 other groups (P < 0.001).
EM Ettema et al.: Effect of Clearance on Copeptin-Vasopressin Ratio CLINICAL RESEARCHand copeptin (b ¼ 0.70; P < 0.001) (Figure 3a). To
investigate the association of copeptin with renal
function per se, this association was therefore stepwise
adjusted for plasma osmolality and for other potential
confounders (age, sex, and blood pressure). The ﬁnal
multivariate model shows that, after adjustment for
these covariates, the association between copeptin and
eGFR remained signiﬁcant (Table 2). Besides eGFR and
plasma osmolality, sex also contributed signiﬁcantly to
copeptin concentration (with women having signiﬁ-
cantly lower values), whereas age and blood pressure
did not.
In univariate analysis, vasopressin was also signiﬁ-
cantly inversely associated with renal function
(Figure 2b) and also an association between plasmaFigure 1. Association of plasma copeptin with vasopressin levels. Gray
patients not on dialysis. Black symbols indicate hemodialysis (HD) patien
Kidney International Reports (2017) 2, 410–419osmolality and vasopressin was found (b ¼ 0.45;
P < 0.001) (Figure 3b). In contrast to copeptin, the
association between vasopressin and renal function was
attenuated after adjustment for plasma osmolality, and
additional adjustment for age, sex, and blood pressure
(Table 3).
As sensitivity analyses, we also added etiology
(i.e., autosomal dominant polycystic kidney disease or
IgA nephropathy) to the univariate analyses, but did
not ﬁnd an effect of etiology on the association between
eGFR and copeptin (b ¼ 0.06; P ¼ 0.41) or on the
association between eGFR and vasopressin (b ¼ 0.12;
P ¼ 0.24). We also added diuretic use separately to the
multivariate analyses because diuretic use might affect
vasopressin and copeptin levels independent of ansymbols indicate healthy participants and chronic kidney disease
ts. eGFR, estimated glomerular ﬁltration rate.
413
Table 2. Associations between plasma copeptin and eGFR in healthy participants and CKD patients not on dialysis
Univariate
Multivariate
Model 1 Model 2 Model 3
b P value b P value b P value b P value
eGFR (ml/min per 1.73 m2) 0.67 <0.001 0.32 0.01 0.31 0.03 0.31 0.03
Plasma osmolality (mOsm/kg) 0.70 <0.001 0.45 <0.001 0.40 <0.01 0.40 <0.01
Age (yr) 0.48 <0.001 0.04 0.68 0.04 0.70
Sexa 0.32 <0.01 0.22 <0.01 0.22 <0.01
SBP (mm Hg) 0.13 0.24 0.02 0.84
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; SBP, systolic blood pressure.
Model 1: adjustment for plasma osmolality. Model 2: as model 1 þ adjustment for age and sex. Model 3: as model 2 þ adjustment for systolic blood pressure.
aMen are considered the reference group.
CLINICAL RESEARCH EM Ettema et al.: Effect of Clearance on Copeptin-Vasopressin Ratioeffect on blood pressure and found that it was not
signiﬁcantly associated with copeptin (b ¼ 0.15;
P ¼ 0.07) or vasopressin (b ¼ 0.16; P ¼ 0.13).
The C/V ratio was inversely associated with renal
function (b ¼ 0.36; P ¼ 0.001), indicating that
copeptin levels rose to a greater extent compared with
vasopressin levels when renal function declined. Break-
point analysis of the association between eGFR and the
C/V ratio in nondialysis subjects indicated a change in
slope at an eGFR of 28 ml/min per 1.73 m2 (Figure 4).
Therefore, the association between renal function and
C/V ratio was analyzed separately for subjects with an
eGFR above and below this threshold. In subjects with
an eGFR above 28 ml/min per 1.73 m2 (n ¼ 60), the
association between eGFR and C/V ratio was not sig-
niﬁcant (b ¼ 0.10; P ¼ 0.46). In contrast, in subjects
with an eGFR below 28 ml/min per 1.73 m2 and not onFigure 2. Associations of renal function with (a) copeptin and (b) vasopre
disease patients not on dialysis. Black symbols indicate hemodialysis (HD
414dialysis (n ¼ 25), eGFR was inversely associated with
the C/V ratio (b ¼ 0.46; P ¼ 0.024). To investigate the
separate associations between renal function and
copeptin and vasopressin in patients with an eGFR >28
and #28 ml/min per 1.73 m2, similar multivariate an-
alyses as performed for the overall group, were also
performed for the 2 subgroups identiﬁed by break-
point analysis (Supplementary Tables S1 and S2).
Remarkably, no associations were found between
vasopressin and renal function or vasopressin and
plasma osmolality in patients with an eGFR
#28 ml/min per 1.73 m2 (b ¼ 0.14; P ¼ 0.52, and
b ¼ 0.14; P ¼ 0.50, respectively). In contrast, in sub-
jects with an eGFR >28 ml/min per 1.73 m2 renal
function and plasma osmolality were signiﬁcantly
associated with vasopressin (b ¼ 0.46; P < 0.001, and
b ¼ 0.54; P < 0.001, respectively) and also withssin. Gray symbols indicate healthy participants and chronic kidney
) patients. eGFR, estimated glomerular ﬁltration rate.
Kidney International Reports (2017) 2, 410–419
Figure 3. Associations of plasma osmolality with (a) copeptin and (b) vasopressin. Gray symbols indicate healthy participants and chronic
kidney disease patients not on dialysis. Black symbols indicate hemodialysis (HD) patients. eGFR, estimated glomerular ﬁltration rate.
EM Ettema et al.: Effect of Clearance on Copeptin-Vasopressin Ratio CLINICAL RESEARCHcopeptin (b ¼ 0.57; P < 0.001, and b ¼ 0.57;
P < 0.001, respectively). In subjects with an eGFR
#28 ml/min per 1.73 m2, copeptin, in contrast to
vasopressin, was associated with renal function and
plasma osmolality (b ¼ 0.56; P ¼ 0.004, and b ¼ 0.60;
P < 0.001, respectively).
Hemodialysis Patients
The mean total ultraﬁltration volume was 2.65 0.67 L.
Twenty of the 42 hemodialysis dialysis patients (48%)
had residual renal function. There was no difference in
age, sex, plasma osmolality, or systolic blood pressure
between patients with and without residual renal
function, but patients without residual renal function
had a signiﬁcantly longer dialysis vintage compared
with that of patients with residual renal function
(Table 4). Patients with residual renal function hadTable 3. Associations between plasma vasopressin and eGFR in healthy
Univariate Mode
b P value b
eGFR (ml/min per 1.73 m2) 0.45 <0.001 0.25
Plasma osmolality (mOsm/kg) 0.45 <0.001 0.26
Age (yr) 0.27 0.01
Sexa 0.16 0.14
SBP (mm Hg) 0.24 0.03
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; SBP, systolic blood p
Model 1: adjustment for plasma osmolality. Model 2: as model 1 þ adjustment for age and se
aMen are considered the reference group.
Kidney International Reports (2017) 2, 410–419signiﬁcantly lower copeptin and vasopressin levels
compared with patients without residual renal function,
but the pretreatment C/V ratio did not differ between
both groups (Table 4). Of note, there was no signiﬁcant
association between dialysis vintage and plasma copep-
tin (b ¼ 0.13; P ¼ 0.40), plasma vasopressin (b ¼ 0.07;
P¼ 0.66) or the C/V ratio (b¼ 0.07; P¼ 0.66). There was
also no correlation between the total ultraﬁltration vol-
ume and the C/V ratio (r ¼ 0.14, P ¼ 0.38).
Effect of Hemodialysis on Copeptin,
Vasopressin, and the C/V Ratio
During hemodialysis, copeptin decreased slightly from
211.0 pmol/l (IQR, 102.4–304.3) to 209.1 pmol/l (IQR,
113.0–312.4) during the ﬁrst half of the dialysis session
(P < 0.01) and increased again during the second half
to 247.3 pmol/l (IQR, 87.2–312.0), that was notparticipants and CKD patients not on dialysis
Multivariate
l 1 Model 2 Model 3
P value b P value b P value
0.11 0.31 0.09 0.33 0.08
0.10 0.23 0.15 0.21 0.18
0.08 0.58 0.11 0.42
0.10 0.33 0.10 0.29
0.18 0.07
ressure.
x. Model 3: as model 2 þ adjustment for systolic blood pressure.
415
Figure 4. Association of renal function with copeptin-vasopressin ratio in healthy participants and in chronic kidney disease patients not on
dialysis. The dotted line indicates the break-point at an estimated glomerular ﬁltration rate (eGFR) of 28 ml/min per 1.73 m2. CI, confidence
interval.
CLINICAL RESEARCH EM Ettema et al.: Effect of Clearance on Copeptin-Vasopressin Ratiosigniﬁcantly different compared with predialysis (P ¼
0.53). Vasopressin followed a similar but more
outspoken pattern, with a decrease during the ﬁrst
hours on dialysis (from 4.9 pmol/l [IQR, 2.5–7.3] to 2.5
pmol/l [IQR, 1.6–3.7], P < 0.01), also followed by an
increase to reach a value of 3.1 pmol/l (IQR, 1.1–5.6),
that was signiﬁcantly different when compared with
predialysis (P ¼ 0.04). Consequently, the C/V ratio
increased signiﬁcantly during the ﬁrst two hours on
hemodialysis and remained higher during the
remainder of the dialysis session.
Plasma vasopressin levels decreased signiﬁcantly
while passing through the dialyzer from 3.9 pmol/l
(IQR, 2.0–5.3) predialyzer to 3.2 pmol/l (IQR, 1.9–4.3)
postdialyzer (P < 0.01), whereas copeptin levels
increased signiﬁcantly from 171.7 pmol/l (IQR,
112.5–296.4) predialyzer to 176.6 pmol/l (IQR,
121.7–352.8) postdialyzer (P < 0.01), presumably as a
result of ultraﬁltration-induced hemoconcentration.
Dialysate concentrations of vasopressin and copeptin
were 0.44 pmol/l (IQR, 0.33–0.59; n ¼ 42) and 1.03
pmol/l [IQR, 0.89–1.31; n ¼ 23], respectively. The
vasopressin and copeptin clearances were 61.5 ml/min







(n [ 22) P value
Age (yr) 67  18 60  18 0.22
Male 17 (85) 13 (59) 0.09
Dialysis vintage (mo) 17.5 (8.3–27.3) 37.5 (21.3–65.5) 0.003
Plasma vasopressin (pmol/l) 4.2 (1.5–5.1) 6.0 (4.6–8.2) <0.01
Plasma copeptin (pmol/l) 115.9 (55.1–215.7) 221.7 (148.6–313.8) 0.01
Copeptin-vasopressin ratio 42.7 (30.1–59.3) 40.4 (31.5–57.4) 0.99
Plasma osmolality (mOsm/kg) 305 (295–307) 307 (299–315) 0.20
SBP (mm Hg) 145  25 142  27 0.64
HD, hemodialysis; RRF, residual renal function; SBP, systolic blood pressure.
Variables are presented as mean  SD, n (%), or median and (interquartile range).
416n ¼ 22), respectively. The clearance of vasopressin was
signiﬁcantly higher than that of copeptin (P < 0.001).
Figure 5 shows the percentage change in plasma levels
of vasopressin and copeptin from predialyzer to
postdialyzer.
DISCUSSION
In this study we investigated the effect of renal
function and hemodialysis on the association between
copeptin and vasopressin levels. We showed that
copeptin and vasopressin were strongly associated in
the overall cohort of participants, including pre-
dialysis subjects. With declining renal function, the
C/V ratio remained constant until an eGFR of 28 ml/min
per 1.73 m2, after which this ratio progressivelyFigure 5. Copeptin and vasopressin concentrations in blood leaving
the dialyzer and in the dialysate compared to the predialyzer
concentration (median and interquartile range).
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higher than for nondialysis patients and healthy in-
dividuals, with no difference between subjects with
and without residual renal function. The C/V ratio rose
during a hemodialysis session, because vasopressin
was cleared by dialysis to a greater extent than
copeptin.
One of the 2 aims of the present study was to assess
whether the C/V ratio remained stable throughout the
full range of renal function to delineate whether
copeptin can be used as a substitute for vasopressin in
patients with impaired renal function. The ratio be-
tween copeptin and vasopressin was investigated once
before in 83 CKD patients with an eGFR ranging from
7 to 61 ml/min per 1.73 m2 by Roussel et al.10 In that
study, it was observed that both copeptin and vaso-
pressin levels were higher in patients with a lower
eGFR. The C/V ratio increased across quintiles of
decreasing renal function and the investigators sug-
gested a greater decrease in renal clearance rate of
copeptin compared with vasopressin when renal
function declines.10 In our study we investigated the
association between renal function and C/V ratio more
closely using break-point analysis. We add that an
association between renal function and C/V ratio is
only found when renal function is severely impaired
(i.e., eGFR #28 ml/min per 1.73 m2). Furthermore, we
also studied copeptin and vasopressin and their ratio in
hemodialysis patients pretreatment and during hemo-
dialysis. Another difference with our study is that
samples were stored frozen during prolonged periods
of time (up to 20 years vs. maximally 1 year in our
study), which may have affected the concentrations of
copeptin and especially vasopressin, as acknowledged
by Roussel et al.10
Copeptin and vasopressin are assumed to be pro-
duced in equimolar amounts.6,8,9 Therefore, we expect
copeptin and vasopressin and their ratio to behave
similarly to changes in volume status. Still, in subjects
with completely normal renal function, that is, an eGFR
>90 ml/min per 1.73 m2, plasma concentration of
copeptin is more than 5-fold higher than that of plasma
vasopressin. This may, at least in part, be caused by a
difference in apparent distribution volume. Vaso-
pressin binds to the V1 and V2 receptors, and bound
vasopressin will be sequestrated from plasma. In
addition, vasopressin binds to platelets29,30 that are
removed by centrifugation during the preanalytic
handling of samples for vasopressin measurement. In
contrast, copeptin is presumably not bound to platelets
and, to our knowledge, no copeptin receptor is known.
Another explanation for lower vasopressin concentra-
tion may be that the half-life of vasopressin is shorter
than that of copeptin. These 3 mechanisms may explainKidney International Reports (2017) 2, 410–419why even in healthy subjects with normal renal
function, the C/V ratio is >1.
When renal function declines, both copeptin and
vasopressin increased. This does not necessarily imply
that these analytes are subject to renal clearance. It is
shown that patients with lower renal function have
impaired urine concentrating capacity.31 Such subjects
tend to have higher plasma osmolality and, conse-
quently, will also have higher vasopressin (and
copeptin) concentration.24,31 Indeed we found signiﬁ-
cant associations between eGFR and plasma osmolality,
and between plasma osmolality and copeptin and
vasopressin. In a previous study we found no associ-
ation between copeptin and renal function in 134
healthy kidney donors predonation and postdonation.
Copeptin levels remained unchanged after kidney
donation, despite a decrease in iothalamate-measured
GFR of w40% (from 105 to 66 ml/min per 1.73 m2).32
These data suggest that not renal clearance per se but
renal disease-induced kidney damage modulates vaso-
pressin and copeptin levels.
Importantly, when eGFR decreases progressively
below 28 ml/min per 1.73 m2, copeptin levels increased
to a greater extent than vasopressin levels, and conse-
quently the C/V ratio increased. On one hand, this
could be explained by a decreased clearance of
copeptin compared with vasopressin. The more marked
copeptin increase in severe renal insufﬁciency indeed
suggests a renal component in the total body clearance
of copeptin. Partial renal clearance of copeptin has been
suggested before, as copeptin has been found in urine.7
Renal clearance, however, will presumably not be the
predominant factor in the degradation of copeptin
because a fast decrease in copeptin levels has been
observed within minutes after the start of water
loading5,7 that is more rapid than one would expect
from renal clearance alone. On the other hand, no as-
sociations between renal function and vasopressin and
between plasma osmolality and vasopressin were
observed in patients with an eGFR #28 ml/min per
1.73 m2. The relatively low vasopressin levels in this
group may, therefore, be attributable to increased
extrarenal clearance of vasopressin. This could also
result in an increase of the C/V ratio in severely
impaired renal function. Vasopressin metabolism has
been studied more extensively, and it has been found
that indeed only 5% to 27% of the total body clearance
is accounted for by the kidneys.33,34 Hepatic vaso-
pressinases35 and endopeptidases and aminopepti-
dases36 seem to play a more important role in
vasopressin clearance. One might also speculate that
accumulation of uremic toxins in severe renal failure
may lead to differences in copeptin and vasopressin
distribution and metabolism. A study on the kinetics of417
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tion, total body clearance and renal clearance, volume
of distribution) and potential physiological effects of
copeptin could clarify this. We want to emphasize that
investigating the exact metabolic fate of copeptin and
vasopressin is beyond the scope of the present clinical
study, as this will necessitate a speciﬁc experimental
design.
The second aim of the present study was to inves-
tigate the kinetics of copeptin and vasopressin during
hemodialysis. The highest C/V ratio was found in he-
modialysis patients. During hemodialysis, the ratio
increased further, indicating that vasopressin was
removed to a greater extent than was copeptin. The
higher dialyzer clearance rate of vasopressin in com-
parison to copeptin is in line with these ﬁndings. Due
to the lower clearance rate of copeptin, accumulation
may occur in the interdialytic interval, provided that
the half-life of copeptin that is associated with extra-
renal clearance mechanisms is long enough. This could,
at least in part, explain the greater increase of copeptin
relative to vasopressin levels in hemodialysis patients.
This study has 2 limitations that need to be
acknowledged. First, copeptin and vasopressin were
measured in samples taken from different studies.
However, in these studies samples were collected ac-
cording to the same strict protocol to ensure optimal
preanalytic sample handling, and copeptin and vaso-
pressin measurements were performed using the same
assays. Inclusion of patients from different studies
explains that the number of participants differed
somewhat between the study groups, that is, healthy
individuals, IgA nephropathy, autosomal dominant
polycystic kidney disease, and hemodialysis patients.
Second, hematocrit levels in the postdialyzer bloodline
was not measured. Therefore, we could not correct the
postdialyzer copeptin and vasopressin levels for
hemoconcentration over the dialyzer, but this does not
affect the measurement of copeptin and vasopressin
clearance by hemodialysis, which was the primary aim
of this part of our study. Strengths of this study are
that we investigated the associations among renal
function, copeptin, vasopressin and their ratio in
detail, and that this study is the ﬁrst to investigate
kinetics of copeptin in relation to vasopressin during
dialysis.
In conclusion, the C/V ratio was stable across the
range of renal function in patients with an eGFR above
28 ml/min per 1.73 m2. Thus, elevated copeptin levels
observed in this eGFR range seem to accurately reﬂect
vasopressin concentration. Consequently, copeptin
seems a suitable marker for vasopressin in healthy
subjects and patients with CKD stages 1 to 3. However,
in studies that include patients with CKD stages 4 and4185, it is necessary to adjust for eGFR when studying
copeptin as a marker for vasopressin. This is important
for future studies in which copeptin is used as a sur-
rogate marker for vasopressin in patients with CKD.
We found no effect of etiology of renal disease on the
association between eGFR and copeptin and vaso-
pressin, which implies that our results might be
generalizable for patients with CKD. In hemodialysis
patients, predialysis copeptin and vasopressin showed
a tight correlation. Copeptin may therefore be used as
surrogate for vasopressin when assessed in blood
samples drawn before dialysis. During a dialysis ses-
sion, however, copeptin and vasopressin show a
different kinetic proﬁle, implying that copeptin does
not adequately reﬂect vasopressin levels during
dialysis.
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